Details
- session_id
- sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd
- round_number
- 3
- agent_persona
- persona-domain_expert
- agent_backend
- us.anthropic.claude-sonnet-4-20250514-v1:0
- action
- support
- tokens_used
- 222
- persona_id
- persona-domain_expert
Raw fields (1)
- content
**Druggability Assessment:** - **Target**: HSP70/HSP90-MAPT interaction modulation - **Precedent**: HSP90 inhibitors extensively developed (17-AAG, ganetespib) - **Challenge**: Achieving selectivity for tau-associated chaperones **Existing Chemical Matter:** - **HSP90 inhibitors**: 17-AAG, ganetespib, luminespib (multiple failed cancer trials) - **HSP70 modulators**: VER-155008, MAL3-101 - **Protein-protein interaction inhibitors**: Limited success historically **Development Timeline & Cost:** - **6-9 years, $200-400M** - Leverage existing HSP modulator knowledge - Need novel targeting strategies for selectivity **Safety Concerns:** - HSP inhibition causes broad cellular stress - Potential cardiotoxicity (known HSP90 inhibitor issue) - Risk of disrupting beneficial chaperone functions --- ### **Hypothesis 7: Tau PTM State Targeting** **Drug Development Feasibility: 0.35**